Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States | Zendy

Corey Neff | Zendy; Gino Cioffi | Zendy; Kristin Waite | Zendy; Carol Kruchko | Zendy; Jill S. BarnholtzSloan | Zendy; Quinn T. Ostrom | Zendy; J. Bryan Iorgulescu | Zendy

AI Assistant Blog Pricing

Open Access

Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States

Author(s) -

Corey Neff,

Gino Cioffi,

Kristin Waite,

Carol Kruchko,

Jill S. BarnholtzSloan,

Quinn T. Ostrom,

J. Bryan Iorgulescu

Publication year - 2022

Publication title -

neuro-oncology practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 14

eISSN - 2054-2585

pISSN - 2054-2577

DOI - 10.1093/nop/npac079

Subject(s) - medicine , odds ratio , glioma , confidence interval , cancer , oncology , odds , logistic regression , cancer research

A newly developed brain molecular marker (BMM) data item was implemented by US cancer registries for individuals diagnosed with brain tumors in 2018-including IDH and 1p/19q-co-deletion statuses for adult-type diffuse gliomas. We thus investigated the testing/reporting completeness of BMM in the United States.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog